A study entitled "The Main Therapeutic Applications of Cannabidiol (CBD) and Its Potential Effects on Aging with Respect to Alzheimer's Disease" that was published in the journal Biomolecules covered "the main pharmacodynamic and pharmacokinetic features of CBD (including characteristics of endocannabinoidome) with respect to its possible beneficial effects on selected diseases in clinical practice," including Alzheimer's disease.
CBD for Alzheimer's Study. The study explained that CBD provides a promising new approach to age management and diseases such as Alzheimer's. "In general, the use of hemp-specific substances and their possible therapeutic use have received increased attention during the past few years.
The study's authors reported that a healthy endocannabinoid system may "induce beneficial effects on the evolution of Alzheimer's disease. They noted that an aging population globally has resulted in an increase in age-related diseases, including Alzheimer's. Because of this, research into cannabinoids such as CBD that might delay or treat Alzheimer's is necessary.
The researchers reported that other pre-clinical studies about CBD have revealed that it "improves both spatial and recognition memory and decreases anxiety in a mouse model of Alzheimer's disease."
"Despite the aforementioned limitations, there is an increasing number of not only preclinical but also clinical research studies (yet small) confirming repeatedly the therapeutic potential of CBD in various pathological conditions. It is recommended to continue with 'lege artis' clinical studies, providing the results that could be utilized in regulatory guidelines for therapeutic applications of CBD in clinical medical care in humans.
"According to all the results of the available clinical studies, CBD has shown clear therapeutic efficacy in the elderly human population. The frequency of side effects is comparable to other classes of drugs, and the risks of using CBD in elderly patients are rated as moderate. However, in geriatric patients, the presence of (a) increased cardiovascular risk, (b) pharmacokinetic changes, and (c) possible interactions with existing, often polypharmaceutical therapy must be considered individually."
Read More, Learn More: Higher Learning LV
